Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
Year: 2009
Type: article
Abstract: The outcome of patients with multiple myeloma is dictated primarily by cytogenetic abnormalities and proliferative capacity of plasma cells. We studied the outcome after initial therapy with lenalidomide-dexamethasone among 100 newly diagnosed patients, risk-stratified by genetic abnormalities and plasma cell labeling index. A total of 16% had high-risk multiple myeloma, defined by the presence of hypodiploidy, del(13q) by metaphase cytogenetics, del(17p), IgH translocations [t(4;14), or t(14;16)] or plasma cell labeling index more than or equal to 3%. Response rates were 81% vs 89% in the high-risk and standard-risk groups, respectively. The median progression-free survival was shorter in the high-risk group (18.5 vs 36.5 months, P < .001), but overall survival was comparable. Because of unavailability of all tests for every patient, we separately analyzed 55 stringently classified patients, and the results were similar. In conclusion, high-risk patients achieve less durable responses with lenalidomide-dexamethasone compared with standard-risk patients; no significant differences in overall survival are apparent so far. These results need confirmation in larger, prospectively designed studies.
Source: Blood
Authors: Prashant Kapoor, Shaji Kumar, Rafael Fonseca, Martha Q. Lacy, Thomas E. Witzig, Suzanne R. Hayman, Angela Dispenzieri, Francis Buadi, P. Leif Bergsagel, Morie A. Gertz, Robert J. Dalton, Joseph R. Mikhael, David Dingli, Craig B. Reeder, John A. Lust, Stephen J. Russell, Vivek Roy, Steven R. Zeldenrust, A. Keith Stewart, Robert A. Kyle, Philip R. Greipp, S. Vincent Rajkumar
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2014073139